Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adaptive Biotechnologies Corp (ADPT)

Adaptive Biotechnologies Corp (ADPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,431,954
  • Shares Outstanding, K 152,665
  • Annual Sales, $ 178,960 K
  • Annual Income, $ -159,490 K
  • EBIT $ -76 M
  • EBITDA $ -65 M
  • 60-Month Beta 2.20
  • Price/Sales 13.38
  • Price/Cash Flow N/A
  • Price/Book 11.51

Options Overview Details

View History
  • Implied Volatility 168.68% (+10.04%)
  • Historical Volatility 94.33%
  • IV Percentile 92%
  • IV Rank 58.38%
  • IV High 247.56% on 02/03/25
  • IV Low 58.02% on 06/13/25
  • Expected Move (DTE 2) 1.42 (8.91%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 26
  • Volume Avg (30-Day) 165
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 2,981
  • Open Int (30-Day) 2,937
  • Expected Range 14.51 to 17.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.19
  • Number of Estimates 4
  • High Estimate -0.18
  • Low Estimate -0.20
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +17.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.28 +19.95%
on 11/18/25
20.76 -23.27%
on 11/25/25
+1.83 (+12.98%)
since 11/14/25
3-Month
12.51 +27.34%
on 09/25/25
20.76 -23.27%
on 11/25/25
+3.02 (+23.39%)
since 09/16/25
52-Week
5.80 +174.42%
on 12/19/24
20.76 -23.27%
on 11/25/25
+9.15 (+134.96%)
since 12/16/24

Most Recent Stories

More News
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive’s proprietary TCR-antigen datasets for research...

ADPT : 15.93 (+1.53%)
PFE : 25.53 (-3.41%)
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease

SEATTLE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

ADPT : 15.93 (+1.53%)
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

ADPT : 15.93 (+1.53%)
Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

ADPT : 15.93 (+1.53%)
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

ADPT : 15.93 (+1.53%)
Adaptive Biotechnologies: Q3 Earnings Snapshot

Adaptive Biotechnologies: Q3 Earnings Snapshot

ADPT : 15.93 (+1.53%)
Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results

SEATTLE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics...

ADPT : 15.93 (+1.53%)
Can This Red-Hot Biotech Stock Live Up to Wall Street’s Expectations?

Adaptive Biotechnologies (ADPT) is a commercial-stage biotech with strong technical momentum. Shares are up 250% in the past year and just hit a new three-year high. ADPT maintains a 100% “Buy” opinion...

ADPT : 15.93 (+1.53%)
Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025

SEATTLE, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

ADPT : 15.93 (+1.53%)
Is Bio-Techne Stock Underperforming the Dow?

Bio-Techne has significantly underperformed the Dow over the past year, but analysts are cautiously optimistic about the stock’s prospects.

TECH : 57.44 (-2.13%)
ADPT : 15.93 (+1.53%)
$DOWI : 48,114.26 (-0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Adaptive Biotechnologies Corporation is a commercial-stage biotech company. It develops and commercializes immune-driven clinical products to transform the diagnosis and treatment of disease. The company's product pipeline includes immunoSEQ, clonoSEQ and cellular therapy which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 16.71
2nd Resistance Point 16.38
1st Resistance Point 16.16
Last Price 15.93
1st Support Level 15.60
2nd Support Level 15.27
3rd Support Level 15.05

See More

52-Week High 20.76
Last Price 15.93
Fibonacci 61.8% 15.05
Fibonacci 50% 13.28
Fibonacci 38.2% 11.52
52-Week Low 5.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar